Sysmex Inostics
Yosuke Baba has a diverse work experience, with their most recent position being the Vice President of Corporate Development at Sysmex Inostics since April 2020. Prior to that, they held the role of Vice President of Business Development at Sysmex Corporation from April 2015 to March 2020. Yosuke also served as the Director of Business Planning at Sysmex Inostics from October 2013 to December 2014. Before joining Sysmex, Yosuke worked at MediBIC as a Senior Consultant from October 2002 to June 2007. Yosuke started their career as a Researcher in the IT Research Laboratory at OMRON Corporation in April 1998 and worked there until September 2002.
Yosuke Baba obtained a Bachelor of Science (BS) in Bioscience from the Tokyo Institute of Technology, from the years 1992 to 1996. Following that, they pursued a Master of Science (M.Sc.) in Neuroscience at Osaka University, from 1996 to 1998.
Sysmex Inostics
Leaders of the Global Liquid Biopsy Revolution As pioneers in blood-based cell-free tumor DNA (ctDNA) mutation detection, Sysmex Inostics has provided custom assays and CLIA-certified lab services to leading BioPharma companies over the last 10 years with the overall goal: to develop therapeutics that extend lives and provide diagnostics to monitor response to therapy, identify targetable resistance alterations, and detect minimal residual disease (MRD). SafeSEQ NGS technology can detect clinically relevant mutations in circulating tumor DNA (ctDNA) with robust detection as low as 0.03% mutant allele frequency (MAF), thus ensuring reliable molecular information for real-time therapy selection as well as monitoring of tumor response from across a broader range of genomic regions.